New indication positions Repatha as an option for high-risk adults with elevated LDL cholesterol and no prior cardiovascular ...

The CDC appointed Retsef Levi, a vocal critic of mRNA Covid-19 vaccines, to lead its Covid-19 immunization workgroup, a panel ...

Under terms of the deal, Gilgamesh could receive up to $1.2 billion as bretisilocin progresses through clinical development ...

BeOne Medicines entered a deal worth up to $950 million with Royalty Pharma selling its rights to global sales royalties of ...

Shiladitya Sengupta, founder, Vyome Therapeutics, explains how the company’s strong ties in India’s biotech and healthcare ...

The science behind NAMs is evolving rapidly, offering innovative, ethically motivated approaches that can enrich mechanistic ...

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...

Michael Grosberg, vice president of product management, spoke with Pharmaceutical Executive about direct-to-consumer sales ...

Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

In a joint statement, 1 the White House and the EU announced the details of what is being called a framework for an agreement ...

Lighthouse Pharmaceuticals receives a $49.2 million grant from the National Institute on Aging, aimed at advancing a Phase 2 ...